IgY antibodies for the immunoprophylaxis and therapy of respiratory infections

Hum Vaccin Immunother. 2019;15(1):264-275. doi: 10.1080/21645515.2018.1514224. Epub 2018 Sep 19.

Abstract

Emergence of drug resistance among the causative organisms for respiratory tract infections represents a critical challenge to the global health care community. Further, although vaccination can prevent disease, vaccine development is impeded by several factors. Therefore, novel approaches to treat and manage respiratory infections are urgently needed. Passive immunization represents a possible alternative to meet this need. Immunoglobulin Y antibodies (IgYs) from the yolk of chicken eggs have previously been used against bacterial and viral infections in human and animals. Their advantages include lack of reaction with mammalian Fc receptors, low production cost, and ease of extraction. Compared to mammalian IgGs, they have higher target specificity and greater binding avidity. They also possess remarkable pathogen-neutralizing activity in the respiratory tract and lungs. In this review, we provide an overview of avian IgYs and describe their potential therapeutic applications for the prevention and treatment of respiratory infections.

Keywords: IgY; immunotherapy; passive immunization; respiratory infection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bacterial Infections / prevention & control
  • Bacterial Infections / therapy
  • Chickens / immunology
  • Egg Yolk / immunology
  • Humans
  • Immunization, Passive*
  • Immunoglobulins / economics
  • Immunoglobulins / therapeutic use*
  • Mice
  • Pre-Exposure Prophylaxis*
  • Respiratory Tract Infections / immunology
  • Respiratory Tract Infections / therapy
  • Virus Diseases / prevention & control
  • Virus Diseases / therapy

Substances

  • IgY
  • Immunoglobulins

Grants and funding

Authors are grateful for financial support from the King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia for providing the grant on MERS-CoV special program (project number 10-1).